Here’s Why Supernus Pharmaceuticals, Rent-A-Center and Three Other Stocks are Down Today

Page 2 of 2

Msci Downgraded by Evercore ISI

New York-based investment decision tool provider MSCI Inc (NYSE:MSCI) has slid by around 5% after financial services firm Evercore ISI downgraded the company to ‘Sell’ from ‘Hold’ and updated its price target to $75 from $81, in a report issued to investors on Tuesday. The firm thinks low costs trend in the industry and passive products will put a pressure on MSCI’s licensing fees. The firm also said the competition in the analytics domain is surging, which could impact the company’s margin expansion plans. Anand Desai’s Darsana Capital Partners is one of 23 funds from our database which are bullish on Msci Inc (NYSE:MSCI).

Follow Msci Inc. (NYSE:MSCI)

Integrated Device Technology Inc (NASDAQ:IDTI)’s stock is down by over 3.8% on volume above average. The company said on Monday that it will announce its fiscal 2017 second-quarter results on October 31. Analysts expect the company to report earnings of $0.33 per share on revenue of $187.12 million. The stock has lost over 19% so far this year. As of the end of the June quarter, 26 funds in our database own shares of Integrated Device Technology Inc (NASDAQ:IDTI).

Follow Integrated Device Technology Inc (NASDAQ:IDTI)

IntelliPharmaCeutics Paring Gains

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)’s investors are in profit-taking mode today after yesterday’s big gains. The stock is down over 7% so far. The Canadian pharmaceutical company announced on Friday it received a tentative FDA approval for its abbreviated new drug application (ANDA) for quetiapine fumarate extended-release tablets. The drug is a generic equivalent for Seroquel XR, which is sold in the US by Astra Zeneca Pharmaceuticals, which has permitted IntelliPharmaCeutics to sell generic versions of the 50, 150, 200, 300 and 400 mg strengths of Seroquel XR after the final FDA approval. Ken Griffin’s Citadel Investment Group owns 14,492 shares of the company as of the end of June.

Follow Intellipharmaceutics Intl Inc (NASDAQ:IPCI)

Disclosure: none

Page 2 of 2